Rivaroxaban for the treatment of deep vein thrombosis and ...

Superseded – See Erratum
difference did not reach statistical significance (p=0.14) this could be due to a small number of events.
Given the marked differences in the health and financial consequences following PE or DVT
conducting an exploratory analysis was deemed prudent. The analysis assumes that;
a. xxxxxx VTEs are DVTs in patients treated with dual therapy LMWH/VKA
b. xxxxxx VTEs are DVTs in patients treated with rivaroxaban
Finally, a cost-minimisation was undertaken assuming the treatment effect to be the same between
rivaroxaban and LMWH/VKA. This scenario assumes that the two drugs provide the same clinical
benefits, but are associated with different costs in terms of drug acquisition, administration and
monitoring.
Results are presented using a lifetime horizon for the PSA results only (1,000 iterations) as the model
showed non-linearity when comparing the results from the deterministic and probabilistic analysis. In
addition to the ICER, the net monetary benefit (NMB) at a WTP of £20,000 or £30,000 per QALY
gained was also reported. A positive NMB indicates that rivaroxaban is cost-effective at the examined
WTP. Finally, the analyses use data by intended treatment duration.
6.1. Probabilistic cost-effectiveness results in patients for whom 3 months of anticoagulation
treatment is appropriate – exploratory analyses conducted by the ERG.
A summary of the analyses undertaken by the ERG are provided in Table 37; care must be taken in
interpreting the cost-effectiveness of interventions which are cost saving but provide a reduction in
overall QALYs.
145
Copyright 2012 Queen's Printer and Controller of HMSO. All rights reserved.